All News

Suicide risk increased among patients who had a lower-income and lived in rural counties following a cancer diagnosis.

Patients with microsatellite instability–high and mismatch repair–deficient advanced endometrial cancer experienced a long lasting benefit following treatment with pembrolizumab.

At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about recommendations to healthcare providers about enrolling their patients into clinical trials for myelofibrosis.

A triplet combination of belantamab mafodotin-blmf plus pomalidomide and dexamethasone yielded a manageable safety profile in a population of patients with relapsed/refractory multiple myeloma.

Enobosarm was granted fast track designation by the FDA for the treatment of patients with androgen receptor–positive, estrogen receptor–positive, HER2-negative metastatic breast cancer.

Patients with stage IB to IIIA non–small cell lung cancer saw an improvement in disease-free survival when treated with pembrolizumab compared with the placebo regardless of PD-L1 expression.

A meta-analysis of 2 phase 3 randomized trials found that combination therapy including androgen deprivation therapy led to higher rates of metastasis-free survival for patients with high-risk non-metastatic prostate cancer.

In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, describes how CAR T-cell therapy for patients with heavily pretreated myeloma has the potential significantly impact response and survival outcomes.

Lindsey Roeker, MD, spoke about phase 2 trial results which demonstrated efficacy of the combination of umbralisib and ublituximab added to ibrutinib for patients with chronic lymphocytic leukemia.

The combination of acalabrutinib, with or without obinutuzumab, produced a strong survival benefit for patients with treatment-naïve chronic lymphocytic leukemia over treatment with ibrutinib or venetoclax plus obinutuzumab.

At 24 weeks, patients with myelofibrosis transfused with serum ferritin and receiving momelotinib experienced a treatment response.

At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about phase 3 trial results regarding myelofibrosis that he is most excited about.

The proposed Most Favored Nation pricing model, which would have had a significant negative impact on cancer care in the United States, has been withdrawn by the Centers for Medicare & Medicaid Services.

The RELATIVITY-047 study highlighted a survival benefit with the combination of relatlimab plus nivolumab compared with nivolumab alone for patients with previously untreated advanced melanoma.

Treatment with CA-4948 monotherapy yielded positive safety data and efficacy for patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome; CI-8993 also appeared to show promise in patients with relapsed/refractory solid tumors.

Findings from a phase 2 study demonstrated encouraging clinical activity and a manageable safety profile when patients with advanced cervical cancer were treated with second-line balstilimab and zalifrelimab.

In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, talks about daratumumab-based quadruplet therapies being evaluated in clinical trials and the potential impact they’ll have on the multiple myeloma treatment landscape.

Investigators believe that storing red blood cells in a hypoxic state could reduce the development of vaso-occlusion flowing transfusion.

Patients with endometrial cancer who were treated with 30 Gy of 6 fractions of vaginal cuff brachytherapy presented with lower toxicity.

Research indicated that non-Hispanic Black patients had significantly worse 5-year overall survival outcomes compared with Hispanic, Asian/Pacific Islander, and American Indian/Alaska Native patients.

Patients with locally advanced or metastatic EGFR exon 20–mutant non–small cell lung cancer may benefit from treatment with CLN-081, which was granted breakthrough therapy designation by the FDA.

A design for the phase 3 ZILO-301 clinical trial, assessing the efficacy of zilovertamab plus ibrutinib for patients with mantle cell lymphoma, has been selected

A synthesis of P-values across 16 studies in different global regions found that socioeconomic status continues to be a significant prognostic factor of overall survival for patients with multiple myeloma.

Telisotuzumab vedotin’s breakthrough therapy designation for EGFR wild-type non–small cell lung cancer was supported by results from the phase 2 LUMINOSITY trial.

IMX-110, which was granted a rare pediatric disease designation for patients with rhabdomyosarcoma, is currently being assessed as part of a phase 1b/2a study.

The combination of quaratusugene ozeplasmid immunogene therapy plus pembrolizumab was granted fast track designation by the US FDA for the treatment of patients with unresectable stage III or IV non–small cell lung cancer who previously progressed on pembrolizumab.

CD123- and CD3-engaging bispecific antibody, APVO436, caused cytokine release syndrome that could be managed through the use of steroids in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.

Patients with relapsed or refractory multiple myeloma may benefit from treatment with teclistamab, for which a biologics license application was submitted to the FDA.

Patients with EGFR-mutated metastatic non–small cell lung cancer may achieve benefit from treatment with patritumab deruxtecan, which was granted breakthrough therapy designation by the FDA.

CYNK-001 was recently granted fast track designation by the FDA for the treatment of patients with acute myeloid leukemia.